Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
23 October 2025
Dear Shareholder,
Neurizon Therapeutics Limited – Annual General Meeting of Shareholders - 26 November 2025
Notice is hereby given that the Annual General Meeting of Shareholders of Neurizon Therapeutics Limited
(Company) will be held as a hybrid meeting at 3.00pm (AEDT) on Wednesday, 26 November 2025 at the
offices of Gilbert + Tobin, Level 25, 101 Collins Street, Melbourne VIC 3000 and also accessible virtually by
an online video-conferencing facility (“Annual General Meeting”, “AGM” or “Meeting”). Notice is also
given that the Company’s Annual Report for the year ended 30 June 2025 (“Annual Report”) is available.
Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options available to
shareholders as to how the communication from the Company can be received. The Company will not
be dispatching physical copies of meeting documents and notices, including the Notice of Meeting for
the AGM, unless you request a physical copy to be posted to you.
The Notice of Meeting, accompanying explanatory statement and Annual Report (“Meeting Materials”)
are being made available to shareholders electronically. This means that:
- You can access the Meeting Materials online at the Company’s website https://www.neurizon.com/
or at the Company’s share registry’s website https://investor.automic.com.au/#/loginsah.
- A complete copy of the Meeting Materials has been posted to the Company’s ASX Market
announcements page at www.asx.com.au under the Company’s ASX code “NUZ”.
- If you have provided an email address and have elected to receive electronic communications from
the Company, you will receive an email to your nominated email address with a link to an electronic
copy of the Meeting Materials and the voting instruction form.
Shareholders can still elect to receive some or all of their communications in physical or electronic form,
or elect not to receive certain documents such as annual reports. To review your communications
preferences or sign up to receive your shareholder communications via email, please update your details
at https://investor.automic.com.au/. If you have not yet registered, you will need your shareholder
information including SRN/HIN details.
If you are unable to access the Meeting Materials online please contact our share registry Automic at
meetings@automicgroup.com.au or by phone on 1300 288 664 (within Australia) or +61 2 9698 5414
(outside Australia) between 9:00am and 5:00pm (AEDT) Monday to Friday, to obtain a copy.
As noted above, the Meeting will be held as a hybrid meeting, meaning that you can attend in person or
online. Details of how to register to attend the meeting online are contained in the Meeting Materials.
Shareholders are encouraged to submit their proxies as soon as possible in advance of the meeting, even
if they are planning to attend the meeting in person or online.
Yours sincerely,
Stefan Ross
Company Secretary
Neurizon Therapeutics Limited
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Notice of Annual General Meeting
Explanatory Statement and Proxy Form
Date of Meeting:
Wednesday, 26 November 2025
Time of Meeting:
3.00pm (AEDT)
Place of Meeting:
Gilbert + Tobin
Level 25, 101 Collins Street
Melbourne VIC 3000
Online access:
https://us02web.zoom.us/webinar/register/WN_EJ-msZhGQdyPs5XmAaKA3Q#/registration
This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety.
If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant,
solicitor, or other professional advisor without delay.
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Registered office: Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000
Notice is hereby given that the Annual General Meeting (AGM or Meeting) of Members of Neurizon
Therapeutics Limited (the “Company”) will be held as a hybrid meeting at 3.00pm (AEDT) on Wednesday, 26
November 2025 at the offices of Gilbert + Tobin, Level 25, 101 Collins Street, Melbourne VIC 3000 and also
accessible virtually by an online video-conferencing facility (“Annual General Meeting”, “AGM” or
“Meeting”).
Recent legislative changes to the Corporations Act 2001 (Cth) mean there are new options available to shareholders as to how
the communication from the Company can be received. The Company will not be dispatching physical copies of meeting
documents and notices, including the Notice of Meeting for the AGM, unless you request a physical copy to be posted to you.
The Notice of Meeting, accompanying explanatory statement and Annual Report (“Meeting Materials”) are being made available
to shareholders electronically. This means that:
- You can access the Meeting Materials online at the Company’s website https://investorhub.neurizon.com/ or at the
Company’s share registry’s website https://www.automicgroup.com.au/ by logging in with your Shareholder Reference
Number (SRN) or Holder Identification Number (HIN).
- A complete copy of the Meeting Materials has been posted to the Company’s ASX Market announcements page at
www.asx.com.au under the Company’s ASX code “NUZ”.
- If you have provided an email address and have elected to receive electronic communications from the Company, you will
receive an email to your nominated email address with a link to an electronic copy of the Meeting Materials and the voting
instruction form.
Shareholders can still elect to receive some or all of their communications in physical or electronic form, or elect not to receive
certain documents such as annual reports. To review your communications preferences, or sign up to receive your shareholder
communications via email, please update your details at https://www.automicgroup.com.au/. If you have not yet registered, you
will need your shareholder information including SRN/HIN details.
Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off date for proxy
voting, being 3.00pm (AEDT) on Monday, 24 November 2025. To lodge your proxy, please follow the directions on your
personalised proxy form.
The Company will conduct a poll on each resolution presented at the Meeting. The Company is happy to accept and answer
questions submitted prior to the Meeting by email to stefan.ross@vistra.com. The Company will address relevant questions during
the Meeting or by written response after the Meeting (subject to the discretion of the Company not to respond to unreasonable
and/or offensive questions).
The AGM will be held as a hybrid meeting whereby Shareholders can attend in person or online.
How do I participate in the meeting online?
Securityholders must use the Automic Meeting Platform to attend and participate in the meeting.
To participate in the meeting, you can log in by entering the following https://portal.automic.com.au/investor/home
on your computer, tablet or smartphone.
Online registration will open 30 minutes before the meeting.
To make the registration process quicker, please have your SRN/HIN and registered postcode or country code ready.
Proxyholders will need to contact Automic prior to the meeting to obtain their login details.
To participate in the meeting online follow the instructions below.
1. Open your internet browser and go to investor.automic.com.au
2. Login with your username and password or click “register” if you haven’t already created an account.
Shareholders are encouraged to create an account prior to the start of the meeting to ensure there is no
delay in attending the virtual meeting
3. After logging in, a banner will display at the bottom of your screen to indicate that the meeting is open for
registration, click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu
bar to access registration.
4. Click on “Register” and follow the steps
5. Click on the URL to join the webcast where you can view and listen to the virtual meeting. Note that the
webcast will open in a separate window.
You can view the meeting live, ask questions verbally or via a live Q&A facility and cast votes at the appropriate times while the
meeting is in progress.
Voting virtually at the Meeting
Shareholders who attend the Meeting remotely are encouraged to vote ahead of the meeting by completing and returning the
proxy enclosed within.
Once the Chair of the Meeting has declared the poll open for voting click on "Refresh" within the platform to be taken to the
voting screen.
Select your voting direction and click "confirm" to submit your vote. Note that you cannot amend your vote after it has been
submitted
For further information on the live voting process please see the Registration and Voting Guide at
https://www.automicgroup.com.au/virtual-agms/
Voting by proxy
To vote by proxy, please use one of the following methods:
Online Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the
instructions: Login to the Automic website using the holding details as shown on the Proxy Form.
Click on ‘View Meetings’ – ‘Vote’. To use the online lodgement facility, Shareholders will need their
holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as
shown on the front of the Proxy Form.
For further information on the online proxy lodgement process please see the Online Proxy
Lodgement Guide at https://www.automicgroup.com.au/virtual-agms/
By post Automic, GPO Box 5193, Sydney NSW 2001
By hand Automic, Level 5, 126 Phillip Street, Sydney NSW 2000
By email Completing the enclosed Proxy Form and emailing it to: meetings@automicgroup.com.au
Chairman’s Letter
23 October 2025
Dear Shareholder,
It’s my pleasure to invite you to the Annual General Meeting (AGM) of Neurizon Therapeutics Limited, which will take
place on Wednesday, 26 November 2025.
The Board recognises that the AGM provides an invaluable opportunity to engage with shareholders, which is why
we will once again be holding a hybrid meeting with a facility for shareholders to attend, ask questions and vote on
the proposed resolutions online, or attend the AGM in person.
We encourage you to participate in the AGM, either in person, online or by proxy, and to vote on the resolutions.
Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off date
for proxy voting, being 3.00pm (AEDT) on Monday 24 November 2025. To lodge your proxy, please follow the
directions on your personalised proxy form.
You may submit your vote online at https://investor.automic.com.au/ using the details provided on the Proxy Form.
If you have any questions regarding the resolutions or the AGM process, please do not hesitate to contact our
Company Secretary, Stefan Ross, at +61 3 9692 7222.
Thank you for your continued support and we look forward to your participation at the AGM.
Yours sincerely,
Sergio Duchini
Chairman
Neurizon Therapeutics Limited
NEURIZON THERAPEUTICS LIMITED
ABN 35 094 006 023
Registered office: Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000
AGENDA
The Explanatory Statement and proxy form which accompany and form part of this Notice, include defined terms and
describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement and the
proxy form in their entirety.
ORDINARY BUSINESS
Receipt and consideration of Accounts & Reports
To receive and consider the Financial Report of the Company, together with the Directors’ Report (including the
Remuneration Report) and Auditor’s Report as set out in the Company’s Annual Report for the year ended 30 June
2025.
Note: Except for as set out in Resolution 1, there is no requirement for Shareholders to approve these reports.
Accordingly, no resolution will be put to Shareholders on this item of business.
Resolution 1: Adoption of Remuneration Report
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That for the purpose of Section 250R(2) of the Corporations Act 2001 and for all other purposes, the Remuneration
Report (included in the Directors' report) for the financial year ended 30 June 2025 be adopted.”
Resolution 2: Re-election of Marcus Hughes as a Director of the Company
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of clause 7.2 of the Constitution, Listing Rule 14.4 and for all other purposes, Marcus Hughes,
who retires by rotation pursuant to the Constitution of the Company in accordance with clause 7.3 of the Constitution
and, being eligible, offers himself for re-election, be re-elected as a Director of the Company.
Resolution 3: Ratification of prior issue of Shares
To consider and, if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve, ratify and confirm
the allotment and issue of 42,249,999 fully paid ordinary shares at an issue price of $0.12 (12 cents) per share in
relation to the Placement to new and existing institutional and professional investors, as described in the Explanatory
Statement."
Resolution 4: Approval to issue shares to Mr Sergio Duchini (or his nominee(s)) in relation to the
Placement
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue 416,667 shares
at an issue price of $0.12 (12 cents) per share in the Company to Mr Sergio Duchini (Non-Executive Chairman of the
Company), or his nominee(s), as part of the Placement announcement on 18 September 2025 on the terms and
conditions set out in the Explanatory Statement which accompanies and forms part of this Notice”
Resolution 5: Approval to issue shares to Mr Marcus Hughes (or his nominee(s)) in relation to the Placement
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue 416,667 shares
at an issue price of $0.12 (12 cents) per share in the Company to Mr Marcus Hughes (Non-Executive Director of the
Company), or his nominee(s), as part of the Placement announcement on 18 September 2025 on the terms and
conditions set out in the Explanatory Statement which accompanies and forms part of this Notice”
Resolution 6: Approval to issue shares to Dr Michael Thurn (or his nominee(s)) in relation to the Placement
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue 166,667 shares
at an issue price of $0.12 (12 cents) per share in the Company to Dr Michael Thurn (Managing Director and CEO of
the Company), or his nominee(s), as part of the Placement announcement on 18 September 2025 on the terms and
conditions set out in the Explanatory Statement which accompanies and forms part of this Notice”
Resolution 7: Approval to issue shares to Dr Katie MacFarlane (or her nominee(s)) in relation to the
Placement
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue 83,334 shares at
an issue price of $0.12 (12 cents) per share in the Company to Dr Katie MacFarlane (Non-Executive Director of the
Company), or her nominee(s), as part of the Placement announcement on 18 September 2025 on the terms and
conditions set out in the Explanatory Statement which accompanies and forms part of this Notice”
SPECIAL BUSINESS
Resolution 8: Amendments to the Company’s Constitution
To consider and, if thought fit, pass the following resolution as a special resolution:
“That, for the purposes of Section 136(2) of the Corporations Act and for all other purposes, approval be given that
the Constitution of the Company be amended in the manner set out in the Explanatory Statement, with effect from
the passing of this resolution.”
Resolution 9: Approval of 10% Placement Facility
To consider and, if thought fit, pass the following resolution as a special resolution:
“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the
issue of Equity Securities up to 10% of the fully paid ordinary securities of the Company (at the time of the issue)
calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the
Explanatory Statement.”
By order of the Board
Stefan Ross
Company Secretary
23 October 2025
NOTES:
(1) Entire Notice: The details of the resolution contained in the Explanatory Statement accompanying this Notice of Meeting should be read
together with, and form part of, this Notice of Meeting.
(2) Record Date: The Company has determined that for the purposes of the Annual General Meeting, shares will be taken to be held by the
persons who are registered as holding the shares at 7.00pm (AEDT) on the date 48 hours before the date of the Annual General Meeting.
Only those persons will be entitled to vote at the Annual General Meeting and transfers registered after that time will be disregarded in
determining entitlements to attend and vote at the Annual General Meeting.
(3) Proxies
a. Votes at the Annual General Meeting may be given personally or by proxy, attorney or representative.
b. Each Shareholder has a right to appoint one or two proxies.
c. A proxy need not be a Shareholder of the Company.
d. If a Shareholder is a company it must execute under its common seal or otherwise in accordance with its constitution, or the
Corporations Act.
e. Where a Shareholder is entitled to cast two or more votes, the Shareholder may appoint two proxies and may specify the proportion
of number of votes each proxy is appointed to exercise.
f. If a Shareholder appoints two proxies, and the appointment does not specify the proportion or number of the Shareholder’s votes,
each proxy may exercise half of the votes. If a Shareholder appoints two proxies, neither proxy may vote on a show of hands.
g. A proxy must be signed by the Shareholder or his or her attorney who has not received any notice of revocation of the authority.
Proxies given by corporations must be signed in accordance with corporation’s constitution and Corporations Act.
h. To be effective, proxy forms must be received by the Company’s share registry (Automic Pty Ltd) no later than 48 hours before the
commencement of the Annual General Meeting, this is no later than 3.00pm (AEDT) on Monday, 24 November 2025. Any proxy
received after that time will not be valid for the scheduled meeting.
i. Online by going to https://investor.automic.com.au/#/loginsah or by scanning the QR code found on the enclosed proxy
form with your mobile device
ii. By post to Automic, GPO Box 5193, Sydney NSW 2001
iii. By hand to Automic, Level 5, 126 Phillip Street, Sydney NSW 2000
iv. By email by completing the Proxy Form and emailing it to: meetings@automicgroup.com.au
(4) Corporate Representative
Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person
with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s representative.
The authority may be sent to the Company and/or registry in advance of the Meeting or handed in at the Meeting when registering as a
corporate representative.
(5) How the Chair will vote Undirected Proxies
Subject to the restrictions set out in Note 6 below, the Chair of the meeting will vote undirected proxies in favour of all of the proposed
resolutions.
(6) Voting Exclusion Statement:
Resolution 1
In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity, including as a proxy),
and the Company will disregard any votes purported to be cast, on this resolution by, or on behalf of, a member of the Key Management
Personnel (KMP), details of whose remuneration are included in the remuneration report, or a Closely Related Party of such a member
(KMP voter), unless the KMP voter is casting a vote on this resolution on behalf of a person who is not a KMP voter (including as a proxy)
and either:
a) the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the resolution; or
b) the KMP voter is by the Chair of the meeting and the appointment of the Chair as proxy:
(i) does not specify the way the proxy is to vote on the resolution; and
(ii) expressly authorises the chair to exercise the proxy even if the resolution is connected directly or indirectly with
the remuneration of a member of the key management personnel for the Company or the consolidated entity.
If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to exercise
the proxy even if the relevant resolution is connected directly or indirectly with the remuneration of a member of the Key Management
Personnel for the Company
If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on Resolution 1, the Chair will vote any proxies
which do not indicate on their Proxy Form the way the Chair must vote, in favour of Resolution 1. In exceptional circumstances, the Chair
may change his or her voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose
to direct the Chair to vote against the Resolution or to abstain from voting.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may
be liable for breaching the voting restrictions that apply to you under the Corporations Act.
Resolution 2
There are no voting exclusions on this resolution.
Resolution 3
The Company will disregard any votes cast in favour of this resolution by or on behalf of any person who participated in the issue of securities
or any associates of that person or those persons.
However, this does not apply to a vote cast in favour of this resolution by:
a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the
proxy or attorney to vote on the resolution in that way; or
b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the chair to vote on the resolution as the chair decides; or
c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on the resolution; and
(ii) the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolutions 4 to 7
The Company will disregard any votes cast in favour of each of Resolutions 4 to 7 (respectively and separately) by or on behalf of:
Mr Sergio Duchini, Mr Marcus Hughes, Dr Michael Thurn and Dr Katie MacFarlane (in respect of each of their stand alone
resolutions only) or any person(s) who will obtain a material benefit as a result of the proposed issue (except a benefit solely by
reason of being a holder of ordinary securities in the entity), or
an associate of person referred to in the preceding paragraph.
However, this does not apply to a vote cast in favour of the resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or
attorney to vote on the resolution in that way; or
(b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given
to the chair to vote on the resolution as the chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of
a person excluded from voting, on the resolution; and
ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolution 8
There are no voting exclusions on this resolution.
Resolution 9
As at the date of dispatch of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule 7.1A.2 and,
therefore, a voting exclusion statement is not required by Listing Rule 7.3A.7.
(7) Restrictions on KMPs voting undirected proxies
A vote must not be cast as proxy on any of Resolution 1 by a member of the Key Management Personnel (as defined by the Corporations
Act) or a closely related party of Key Management Personnel.
However, a person described above (a “Restricted Voter”) may cast a vote on any of Resolution 1 as a proxy if:
(a) The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the resolution(s); and
(b) The Chair is the Restricted Voter and the written appointment of the Chair as proxy does not specify the way the proxy is to vote
on the resolution(s) or expressly authorises the Chair to exercise the proxy even though the resolution(s) is or are connected with
the remuneration of a member of the Key Management Personnel.
If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to exercise
the proxy even if the relevant resolution is connected directly or indirectly with the remuneration of a member of the Key Management
Personnel for the Company.
(8) Special Resolution
Resolutions 8 and 9 are proposed as special resolutions. For a special resolution to be passed, at least 75% of the votes validly cast on the
resolution by Shareholders (by number of shares) must be in favour of the resolution.
(9) Enquiries
Shareholders are invited to contact the Company Secretary, Stefan Ross on +61 3 9692 7222 if they have any queries in respect of the
matters set out in these documents.
EXPLANATORY STATEMENT
Purpose of Information
This Explanatory Statement (“Statement”) accompanies and forms part of the Company’s Notice of Annual General
Meeting (“Notice”) for the 2025 Annual General Meeting (“Meeting”) to be held as a hybrid meeting at 3.00pm (AEDT)
on Wednesday, 26 November 2025 at the offices of Gilbert + Tobin, Level 25, 101 Collins Street, Melbourne VIC
3000 and also accessible virtually by an online video-conferencing facility.
The Notice incorporates, and should be read together, with this Statement.
Receipt and consideration of Accounts & Reports
A copy of the Annual Report for the financial year ended 30 June 2025 (which incorporates the Company's financial
report, reports of the Directors (including the Remuneration Report) and the auditors) is not enclosed as there is no
longer a requirement for the Company to incur the printing and distribution cost associated with doing so for all
Shareholders. You may obtain a copy free of charge in hard copy form by contacting the Company Secretary at
stefan.ross@vistra.com, and you may request that this occurs on a standing basis for future years.
Alternatively, you may access the Annual Report at the Company's website www.neurizon.com or via the Company's
announcement platform on ASX under the ASX Code “NUZ”. Except as set out in Resolution 1, no resolution is
required on these reports.
Shareholders will have the opportunity to ask questions about or make comments on the 2025 Annual Report and
the management of the Company. The auditor will be invited to attend, to answer questions about the audit of the
Company’s 2025 Annual Financial Statements.
ORDINARY BUSINESS
Resolution 1: Adoption of Remuneration Report
Background
Section 250R(2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put to
the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the Directors
or the Company.
The Remuneration Report is set out in the Directors’ Report in the Company’s 2025 Annual Report. The
Remuneration Report sets out the Company’s remuneration arrangements for the Directors and senior management
of the Company.
In accordance with Section 250SA of the Corporations Act, Shareholders will be provided with a reasonable
opportunity to ask questions concerning, or make comments on, the Remuneration Report at the Annual General
Meeting.
In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes that
are cast are voted against the adoption of the Remuneration Report at two consecutive Annual General Meetings,
Shareholders will be required to vote at the second of those Annual General Meetings on a resolution (a “spill
resolution”) that another meeting be held within 90 days at which all of the Company’s Directors (other than the
Managing Director) must go up for re-election.
It is noted that at the Company’s last Annual General Meeting, the votes cast against the Remuneration Report
represented less than twenty-five (25%) per cent of the total votes cast on that resolution and accordingly, a spill
resolution will not under any circumstances be required for the Meeting.
The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration
Report at the Meeting when
Share your feedback
Discover